Vilnius University Hospital

The Oncology Department in Vilnius is conducting a broad portfolio of studies focused on neoplasms, with a strong emphasis on improving outcomes for patients with lung cancer, prostate cancer, melanoma, and gastrointestinal cancers. These trials are mainly designed to test new treatment strategies, compare them with current care, and better understand which approaches can extend survival or reduce disease progression.

• Studies in non-small cell lung cancer and small-cell lung cancer are evaluating new immunotherapy and combined treatment approaches to improve survival and disease control.
• Research in prostate cancer, including metastatic hormone-sensitive prostate cancer and metastatic castrate-resistant prostate cancer, is examining therapies that may better suppress disease progression and manage advanced illness.
• Trials in melanoma are comparing innovative immune-based treatments and biosimilar options to help refine care for advanced or resected disease.
• Work in gastric cancer, esophageal cancer, and gastroesophageal junction adenocarcinoma is focused on improving first-line and perioperative treatment effectiveness.

Overall, this site is contributing to research that spans advanced solid tumors and includes efforts to improve survival, tumor response, and the effectiveness of modern cancer therapies.

A major part of the clinical research at this hospital centers on respiratory tract diseases, especially non-small cell lung cancer and limited-stage small-cell lung cancer. The studies are exploring whether newer immunotherapy, targeted therapy, and combined treatment plans can improve outcomes for people with locally advanced or metastatic disease.

• Trials in NSCLC are assessing treatment strategies for both newly diagnosed and previously treated patients, with attention to survival and response rates.
• Research in small-cell lung cancer is examining whether adding immunotherapy after standard treatment can help patients live longer.
• Some studies are also looking at treatment combinations for stage III lung cancer to improve control of disease after chemoradiation.
• The overall goal is to identify more effective options for difficult-to-treat lung cancers while supporting better long-term outcomes.

This work reflects a strong focus on testing modern cancer immunotherapy and targeted treatment approaches in lung oncology.

Although the site’s trial activity is dominated by oncology, it also falls within the broader area of congenital, hereditary, and neonatal diseases and abnormalities, showing interest in conditions where inherited biology and tumor behavior may intersect. At Vilnius University Hospital, this therapeutic area is represented through studies that may support more precise diagnosis and treatment selection in cancer care.

• Research in this area may help clarify how inherited or molecular features influence treatment response in cancer.
• Some trials are focused on biological markers and tumor characteristics that can guide more personalized treatment decisions.
• The work supports a broader effort to match therapies more closely to each patient’s disease profile.
• These studies contribute to a more individualized approach to care, especially for patients with advanced or hard-to-treat disease.

In practice, this area overlaps with oncology research by helping explain why some patients respond differently to the same treatment.